Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
Richard Langley, Steven R. Feldman, Judit Nyirady, et al.
Journal of Dermatological Treatment (2013) Vol. 26, Iss. 1, pp. 23-31
Closed Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Richard Langley, Boni E. Elewski, Mark Lebwohl, et al.
New England Journal of Medicine (2014) Vol. 371, Iss. 4, pp. 326-338
Open Access | Times Cited: 1818
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, et al.
Journal of the American Academy of Dermatology (2015) Vol. 73, Iss. 3, pp. 400-409
Open Access | Times Cited: 514
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim Papp, Andrew Blauvelt, Michael Bukhalo, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 16, pp. 1551-1560
Open Access | Times Cited: 463
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial
Richard Langley, Tsen‐Fang Tsai, Susan Flavin, et al.
British Journal of Dermatology (2017) Vol. 178, Iss. 1, pp. 114-123
Open Access | Times Cited: 306
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
Andrew Blauvelt, Jörg C. Prinz, Alice B. Gottlieb, et al.
British Journal of Dermatology (2014) Vol. 172, Iss. 2, pp. 484-493
Closed Access | Times Cited: 305
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
P.C.M. van de Kerkhof, C.E.M. Griffiths, Kristian Reich, et al.
Journal of the American Academy of Dermatology (2016) Vol. 75, Iss. 1, pp. 83-98.e4
Closed Access | Times Cited: 296
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, et al.
Journal of the American Academy of Dermatology (2016) Vol. 76, Iss. 1, pp. 60-69.e9
Closed Access | Times Cited: 284
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul, J.‐P. Lacour, L. Tedremets, et al.
Journal of the European Academy of Dermatology and Venereology (2014) Vol. 29, Iss. 6, pp. 1082-1090
Closed Access | Times Cited: 269
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Iain B. McInnes, J. Anderson, Marina Magrey, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 13, pp. 1227-1239
Open Access | Times Cited: 221
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J. Mease, Apinya Lertratanakul, J. Anderson, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 312-320
Open Access | Times Cited: 199
An update on generalized pustular psoriasis
Melinda Gooderham, Abby S. Van Voorhees, Mark Lebwohl
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 9, pp. 907-919
Open Access | Times Cited: 195
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni, et al.
Journal of the American Academy of Dermatology (2015) Vol. 73, Iss. 1, pp. 27-36.e1
Closed Access | Times Cited: 186
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
C.E.M. Griffiths, Diamant Thaçi, Sascha Gerdes, et al.
British Journal of Dermatology (2017) Vol. 176, Iss. 4, pp. 928-938
Open Access | Times Cited: 172
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis
Mark Lebwohl, Leon Kircik, Angela Moore, et al.
JAMA (2022) Vol. 328, Iss. 11, pp. 1073-1073
Open Access | Times Cited: 80
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice B. Gottlieb, John Sullivan, Martijn B. A. van Doorn, et al.
Journal of the American Academy of Dermatology (2016) Vol. 76, Iss. 1, pp. 70-80
Open Access | Times Cited: 141
Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR )
Satveer K. Mahil, Nina Wilson, Nick Dand, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 5, pp. 1158-1166
Open Access | Times Cited: 120
Secukinumab: First Global Approval
Mark Sanford, Kate McKeage
Drugs (2015) Vol. 75, Iss. 3, pp. 329-338
Closed Access | Times Cited: 110
Trial of Roflumilast Cream for Chronic Plaque Psoriasis
Mark Lebwohl, Kim Papp, Linda Stein Gold, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 3, pp. 229-239
Open Access | Times Cited: 101
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel, Kristina Callis Duffin, Angela Moore, et al.
Journal of the American Academy of Dermatology (2017) Vol. 77, Iss. 4, pp. 667-674
Open Access | Times Cited: 99
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus
Ulrich Mrowietz, Juliet N. Barker, Wolf‐­Henning Boehncke, et al.
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. S3, pp. 3-14
Open Access | Times Cited: 95
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Kim Papp, Mark Weinberg, A. O. Morris, et al.
The Lancet (2021) Vol. 397, Iss. 10284, pp. 1564-1575
Closed Access | Times Cited: 95
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis
K. Thomas Robbins, Robert Bissonnette, Tomoko Maeda‐Chubachi, et al.
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 3, pp. 714-721
Closed Access | Times Cited: 84
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 3, pp. 475-485
Open Access | Times Cited: 73
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C. Coates, Laure Gossec, Elke Theander, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 359-369
Open Access | Times Cited: 69
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
Philip J. Mease, Apinya Lertratanakul, Kim Papp, et al.
Rheumatology and Therapy (2021) Vol. 8, Iss. 2, pp. 903-919
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top